Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Lidak Pharm. [LDAKA] -- Ignore unavailable to you. Want to Upgrade?

To: Ronald Forbes who wrote (772)	1/2/1998 11:25:00 AM
From: Henry Volquardsen	Read Replies (1) \| Respond to of 1115

Ron, I posted my thoughts yesterday in the following post Message 3072195 as I said then I suspect there was some sort of conflict of interset. From what the company has released regarding the phase 3 and Katz's decision to increase his stake makes me believe the problem is not with Lidakol. I think the comment in wednesday's pr that BMY's cancellation was not prompted by therapeutic reasons reenforces this opinion. How long is a little while? The depends on one or two of three different things happening; Lidak announcing the details of the phase 3 trials including comparisons vs the placebo, Lidak announcing the specific reasons why BMY canceled or Lidak announcing a new marketing agreement. And there is a new years bump, just in the wrong direction :( Henry